ABSTRACT Motivation: Automatic procedures to obtain pharmacophore models from experimentally determined macromolecular complexes can help in the drug discovery process, especially when protein-protein recognition plays an important biological role. Results: The GRID-based pharmacophore model (GBPM) is a fully objective method for defining most relevant interaction areas in complexes deriving pharmacophore models from three-dimensional (3D) molecular structure information. It is based on logical and clustering operations with 3D maps computed by the GRID program on structurally known molecular complexes. In this manuscript we describe the concept and discuss application examples regarding protein-protein recognition. In particular two complexes selected in the Protein Data Bank have been tested to evaluate the GBPM capability to identify interaction areas. The results obtained show the capabilities of this new bioinformatic method. Availability: The GBPM method has not been developed as a new computational code. It is based on the combination of existing scientific programs.
INTRODUCTION
Pharmacophore models are useful tools for drug discovery and lead optimization processes (Milne, 1998) . Usually they are created collecting most relevant structural features of biological active molecules. In most cases chemical intuition is necessary for completing the pharmacophore generation, in ambiguous cases possibly leading to erroneous models. One of the most advanced application of pharmacophore model is the virtual screening of large compound databases against multiple macromolecular targets ( Langer and Krovat, 2003) . This emerging bioinformatic technique, now considered as a new source of novel drug leads (Alvarez, 2004) , is more and more attracting the interest of industrial pharmaceutical research.
Among the most trusted computational methodologies widely adopted in drug design studies, Goodford's GRID program (Goodford, 1985) is very well accepted in the scientific community. It works by mapping the three-dimensional (3D) space around molecular targets with probes, recently re-parameterized (Carosati et al., 2004) , mimicking the chemical properties of most common atom types and small moieties to be found in ligands. GRID data can be used to identify best probe locations as map display as well as 3D information for chemometric analysis (Pastor et al., 1997; Kastenholz et al., 2000; Pastor et al., 2000; Crivori et al., 2000) . The large availability of crystal and NMR structures of macromolecular complexes deposited into the Protein Data Bank (PDB) is an excellent source for studying interactions between molecules of different nature including proteins, nucleic acids and small organic ligands (Berman et al., 2000) .
In this study we have developed a general computational procedure to generate automatically and objective pharmacophore models starting with PDB complexes. We have logically combined maps computed with the GRID methodology in order to derive the essential information of the interaction between the molecules of a PDB complex to export into a pharmacophore hypothesis. The versatility of the computational method has been tested in two application examples using molecular complexes of different nature.
METHODS
The GRID-based pharmacophore model (GBPM) is created in a 6-step procedure as depicted in Figure 1 .
The first step is dedicated to the PDB file pretreatment. It often contains water molecules and no hydrogen atoms. In the pretreatment the user should fix typical problems such as missing residues, missing side chains and wrong bond orders especially for bound organic compounds. The GREAT and GRIN modules of the GRID software help to this task and allow the preparation to the GRID mapping procedure. Assuming that the complex has two interacting molecules a and b, as in the case of protein-protein complexes, the main goal of this first step is to get three structures, respectively, with the a + b, a and b subunits keeping the atomic coordinates of the original PDB model (Fig. 1) .
The second step performs the GRID calculation with a given probe onto the three subunit models. In order to make the comparison of the map files as easy as possible, the matrix dimension of the GRID box is exactly maintained as in the largest model, i.e. that with a + b subunits, taking into account, for both subunits, the original complex atom coordinates. The three maps obtained are, respectively, named A, B and C (Fig. 1) .
The third step is based on the GRAB program, implemented in GRID v. 21. Such a utility energetically compares two generic A and B GRID maps generating a D resulting map. GRAB adopts for each node (n) of A and B the following algorithm: if n A > 0 and n
. The resulting map D, in our case map B-map A, has, by Ã To whom correspondence should be addressed. definition, the same matrix dimension of the original maps and reports, with negative energy values, the ab interaction. According to the GRAB algorithm the a components are converted into positive or zero values comparing map D-map C. The resulting map E reports the acceptance degree of a certain probe into the ab binding site. Such an indication represents a first, interesting, advantage of the GBPM method, because no biased indication has been given about the location and the extension of the map E and then about the interaction area. A graphical representation of GRAB procedues is displayed in Figure 2 . The fourth step is dedicated to the identification of most relevant interaction points of map E. This task is carried out using the MINIM utility included into the GRID program. Such a program collects all points within a certain energy threshold allowing the interpolation of the closest ones. The choice of an energy threshold value is a biased task per se but, considering a pharmacophore model as a minimum interaction descriptor built by few features, we have generally found appropriate an energy threshold in the range of 5-15% higher than the global minimum value. Actually, such a threshold allows collecting at least one feature for each used probe. Often the above energy threshold yields to complicated pharmacophore models that can be reduced using the GRID energy as cutting criterion.
In order to design a suitable model, all reported operations should be repeated using at least three different probes: the hydrophophic probe (DRY), an hydrogen bond acceptor (HBA) (O) and an hydrogen bond donor (HBD) (N1). This choice allows a basic characterization of most interaction areas, however, more sophisticated and selective models can be obtained by adding other GRID probes such as halogen or charged atoms, for example when those are part of the subunit a or of known interacting ligands.
In the fifth step the information originating from the different probe experiments are simply merged, by a trivial text editing, into a preliminary model stored in PDB file format (multiple features of Fig. 1 ).
The sixth step is dedicated to the validation of these preliminary informations and eventually their modulation in terms of number of points (features). The quality of the model is tested at least as the capability to recognize the original PDB ligand (a subunit). Technically the evaluation step can be carried out by the Catalyst software (Accelrys, 2003, http://www. accelrys.com) using the CiTest fit module which calculates a non-energy weighted fit value. The preliminary model is imported converting the GBPM points into Catalyst features. The GRID energies are also included in the fit analysis as feature weight according to the following Equation (1):
where wFij is the weight for the feature i into the hypothesis j, EFi is the GRID energy for the features i and AEFj is the average GRID energy value computed along all probes of the hypothesis j. This approach allows to have a maximum fit value (MFV) equal to the total number of features available for the hypothesis j. Taking into account the GRID energies several preliminary models (hypotheses) can be designed modulating the number of features. Unfortunately due to the high variability, i.e. extension and interaction type, of the a-b subunit interface the number of preliminary models cannot be predefined. So, in order to identify the best one, all possible models are submitted to CiTest fit. A fit index (FI), defined as ratio between the CiTest fit and MFV is used for the evaluation of each hypothesis and as choice criterion for the identification of the best GBPM.
Moreover, the FI descriptor, which makes possible the comparison among models with different number of features, can be used to extend the evaluation step including other molecules known to interact with the same b subunit binding site. Such an eventuality strongly improves the quality of the final model.
RESULTS
In order to check the versatility of the GBPM method, two different protein-protein complexes selected from PDB were extensively tested. In terms of complexity this kind of interaction is definitively more critical than other recognition phenomena such those of ligand-enzyme or drug-DNA complexes.
X-linked inhibitor of apoptosis
The protein-protein case study is related to the X-linked inhibitor of apoptosis (XIAP). Its third baculovirus IAP repeat domain (BIR3) recognizes molecules 1-5 shown in Figure 3 . The structure of peptide 1 has been determined by NMR and is deposited in 1G3F PDB entry (Liu et al., 2000) . Protein 2 conformations were isolated from 1XB0 and 1XB1 models (Shin et al., 2005) . Five conformations of molecule 3 were considered from the 1XB0 model. Another conformation of this peptide was extracted from the chimera 1TW6 structure (Vucic et al., 2005) . From the same PDB model also molecule 4 was obtained. The conformation of the peptidomimetic 5 was obtained from the 1TFQ model (Oost et al., 2004) . Finally the Smac protein 6, complexed with XIAP, was considered using the 1G73 PDB crystallographic model (resolution 2.00 s). Since 6 is significantly larger than molecules 1-5 the recognition with XIAP is not exclusive of the BIR3 domain, but involves additional regions. A pharmacophore model able to describe entirely this kind of recognition is technically feasible but useless for the virtual screening of 3D databases, because it will eventually be appropriate to identify high molecular weight molecules with improbable drug-likeness properties. So the GBPM was derived using the 1G3F original PDB complex in which is reported the recognition of the relatively small synthetic peptide 1 and XIAP BIR3 domain. Moreover 1 is the largest among 1-5 ligands allowing a more exhaustive description of the interaction area.
The XIAP recognition area with caspase 9 is quite extended, about 700 s 2 (Huang et al., 2001) , several hydrophobic, electrostatic and hydrogen bond interactions are involved, so a simple receptor-based pharmacophore model results relatively hard to derive. Moreover the very low number of molecules, known to recognize the XIAP BIR3 domain, does not allow a rigorous classic ligand-based approach. For these reasons GBPM represents a potentially useful tool for the XIAP case study.
The computational work has been carried out following the flow chart reported in Figure 1 . After the pretreatment step 1, the peptide 1 has been considered as a subunit and the XIAP as the b one. The 1G3F PDB complex has been used to compute GRID molecular interaction field with O, N1 and DRY probes (maps A). These procedures, using the same complex box dimensions, have been repeated separately onto the a (maps B) and the b (maps C) subunits maintaining, in both cases, their original complex atom coordinates (Step 2). Maps A and B have been compared by GRAB algorithm obtaining the maps D that have been used, together with maps C, to obtain maps E (Step 3). The three maps E have been submitted to MINIM with interpolation option, using an energy threshold of 1 kcal/mol above the global minimum. This approach results into four features with one N1 probe, three with DRY and only one with O. The preliminary model (Hyp1-1G3F) has been imported into the Catalyst program using for each probe the chemically closest feature as follows: the HBD for N1, the generic hydrophobic (HPB) for DRY and the HBA for O. The weight of each features has been scaled taking into account the GRID interaction energies using Equation (1).
The resulting nine features Hyp1-1G3F model has been tested, with both rigid and flexible CiTest algorithm, using ligand 1. Since the resulting FI index, equal to 0.02, revealed a poor recognition of peptide 1 Hyp1-1G3F was simplified by removing the less relevant HBD HDB3 and HDB4 features and rescaling the weight of the remaining ones as reported for Hyp1-1G3F. The evaluation of a new seven-features model, Hyp2-1G3F, indicated a better fit with 1 (FI index increased to 0.57). The simplification of the pharmacophore model proceeded by iterative elimination of the less relevant features adjusting the weight of the remaining ones. With the aim to improve the selective recognition capabilities and taking into account the presence of a positively charged N-terminus on molecules 1-5, we introduced the positive ionizable feature, POS. This task has been carried out including in the GBPM flow chart (Fig. 1) the GRID probe N+. The single feature map revealed for the N+ only one point within the first kcal/mol with respect to its global minimum. Its interaction energy, equal to À17.88 kcal/mol, has been the most relevant with respect to all other probes. Interestingly the location of this point was coincident with the HDB1 one, which has showed an interaction energy equal to À7.31 kcal/mol. Consequently we built a new model, Hyp3-1G3F, substituting HDB1 with POS rescaling the feature weights, with superior FI value equal to 0.95.
Hyp3-1G3F then has been evaluated with respect to 2-5. With all molecules, taking into account all their experimental determined conformations, FI values higher than 0.90 have been reached confirming the high degree of recognition of known molecules interacting with XIAP BIR3 domain of Hyp3-1G3F (Fig. 4) . In some cases, especially with 2, equivalent features overlap different ligand regions, despite the compounds share a common fragment. The explanation can be likely addressed to the Catalyst fit algorithm, that in presence of identical types of close chemical groups, prefers the best score overlap obtaining differences even among similar derivatives. The appropriate modulation of features, basing on GRID energy values, allows in the XIAP case study the identification of a GBPM able to recognize with high FIs all crystallographic ligands of the BIR3 domain. Notably this result has been obtained working with the 1G3F PDB model only.
Interleukin 8 dimer
The GBPM evaluation in protein-protein case studies has been extended analyzing the interleukin 8 (IL8) dimer. This cytokine plays a relevant role in immune cells trafficking and in host defense against infection. It is known that IL8 can exist in both dimer and monomer forms, but this last only is able to productively interact with the CXCR receptors (Fernando et al., 2004) . Then the equilibrium between dimer and monomer forms can be considered as an interesting target for modulating the IL8 activity. In the present study we designed a GBPM pharmacophore model for the IL8 dimer interface which could be useful for searching molecules modulating the equilibrium between active and inactive forms of IL8.
Our study has been carried out using the NMR-derived PDB model 1IL8 which represents an average structure of the IL8 homodimer in solution (Clore et al., 1990) . To apply the GBPM approach, taking into account the general scheme reported in Figure 1 , the 1IL8 chain A has been considered as subunit b while the chain B was the a one (Fig. 5) .
GRID probes O, N1 and DRY have been used in the 1IL8 case study. The preliminary pharmacophore model (Hyp1-1IL8) for the IL8 dimer interface has been designed selecting for each probe map E all points with an interaction energy within 1 kcal/mol above the global minimum. As shown in Figure 6 , such a model was built by 20 hydrophobic features (HPB), 6 HBDs and 5 HBAs.
As observed in all our GBPM application, the first model, due to the large number of its features, is useless as a pharmacophore model for screening, but useful for characterizing the complex interactions. We have included Hyp1-1IL8 into the discussion of the IL8 case study because no ligands are known for their interaction with the IL8 dimer interface, then we have considered the recognition of the first model to evaluate the applicability of the GBPM onto this protein-protein case study. As reported in Figure 6 , our approach has been able to recognize the target. Notably several residues, indicated in Figure 6 and reported by Clore into the 1IL8 paper for their relevance into the IL8 dimerisation, have been identified. Moreover GBPM identified other aminoacids located to the dimer interface that could contribute to the equilibrium between the active and inactive forms of the IL8. These observations have allowed us to positively consider the application of GBPM to the IL8 case study. In order to design a more suitable pharmacophore model we have reduced the total number of features of Hyp1-1IL8 removing the points with higher interaction energy. The best of the models obtained by Hyp1-1IL8 simplification, indicated as Hyp2-1IL8, showed an FI equal to 0.80 and a good recognition of the dimerization region.
In Figure 7 the IL8 dimerization interface recognition of Hyp2-1IL8 and its feature composition has been reported.
Even if no ligand validation has been possible for the present case study, we considered IL8 as a good application for the GBPM. Since no pharmacophoric information is available for the dimer interface, our method, validated by the recognition of the original ligand, represents a potentially useful model for virtual screening purposes.
CONCLUSIONS
The GBPM have been developed with the aim to define a general computational protocol for characterizing interaction between any kind of biomolecules creating pharmacophore models starting from well referenced experimental complex models such as those deposited in the PDB. It is different from traditional pharmacophore model because no information about the activity is explicitly included in its development. The assumption is that if a consistent recognition between two or more biomolecules can occur and be determined by spectroscopic accurate methods, typically as in cocrystal models of the PDB, their high degree of reciprocal affinity should be summarized by relevant features. The aim of the GBPM approach is to convert the affinity information of experimentally known complexes into a new kind of pharmacophore model, implementing an energy-based criterion. The preliminary validation of the methodology in two diverse kind of protein-protein complexes is going to be extended further also to other examples, however, the results obtained so far already indicate the high versatility of the GBMP approach.
The examples described in the present work revealed good capabilities of our method to identify the most relevant host-guest occurring interaction into the analyzed complexes independently from their chemical nature. It is worth noting that when particular physico-chemical features are found in the ligands, as in the former case study with charged moieties, appropriate probes can dramatically influence the results and therefore must be incorporated into the analysis. GBPM has revealed no impediments for its application on macromolecular targets. Due to the large number of GRID probes available, a notable improvement of the generated pharmacophore models can be achieved suggesting also new substituents for known ligands. Consequently, the GBPM approach could represent a useful bioinformatic tool for the recognition analysis of biomolecules. Future work will focus on possible applications of the GBPM method in the field of the drug discovery process. 
